Bausch + Lomb (NYSE:BLCO) posts Q3 2026 profit well ahead of estimates
Bausch + Lomb (BLCO) reported Q3 2026 revenue of $1.38B, matching estimates and growing 7.3% YoY. Adjusted EPS of $0.34 beat estimates by 54.7%. Adjusted EBITDA was $325M, a 23.6% margin and 20% beat. The company raised full-year revenue guidance to $5.5B and EBITDA to $1.12B, both above estimates. Operating margin improved to 11.3%.
How this was made
The 30-second read
Why it matters
The combination of an adjusted EPS beat, EBITDA beat, higher operating margin, and guidance midpoints above consensus is likely to trigger upward estimate revisions and support the stock near-term.
Market read
Traders can reassess near-term expectations and valuation given the explicit guidance midpoint increases and margin improvement.
What to watch
Focus on whether the margin expansion is sustainable and whether constant-currency growth acceleration persists beyond the quarter.
Background
The article summarizes Bausch + Lomb’s Q3 2026 financial performance versus S&P analysts’ consensus and notes guidance changes for the full year.
Ticker impact
Bausch + Lomb reported Q3 2026 adjusted EPS of $0.34 versus $0.22 consensus and lifted full-year revenue guidance to $5.5B midpoint.
Likely upward pressure as the market digests the guidance midpoint increases and margin improvement.
The article provides multiple above-consensus beats (EPS, EBITDA) and explicit guidance midpoints above consensus, which typically drives positive earnings revisions and sentiment.
Market effects
Improves sentiment for specialty pharma and medtech-adjacent names by reinforcing demand and margin resilience signals.
Limited direct regional spillover beyond US large-cap healthcare sentiment.
Modest, as the disclosure is company-specific rather than a global macro or regulatory shift.
Counterpoint
The guidance lift is described as slight, so upside may be capped if investors were already positioned for a beat.
Key entities
- companyBausch + Lomb
Reported Q3 2026 results and slightly lifted full-year revenue and EBITDA guidance.
